spacer
home > > autumn 2009 > monitoring progress
PUBLICATIONS


Monitoring Progress

Data monitoring committees (DMCs) are frequently used to oversee accruing data from large, pivotal double blind clinical trials where the objective is to demonstrate safety and efficacy. The various roles of the DMCs are often not fully understood or appreciated. DMCs serve two primary functions: to ensure the ethics of the clinical trial, and to provide assurance that basic objectives of the trial have a reasonable likelihood of success.

The ethical mandate is to ensure that patients are not put at undue risk by their participation in the clinical trial. Ensuring patient safety is the primary responsibility of a DMC. A DMC monitors safety outcomes as the trial is ongoing and provides a mechanism to quickly react to any untoward safety events.

The assurance objective is to use DMCs to oversee and monitor the general trial progress. These large trials represent a significant commitment of time and resources, and a DMC provides a means of monitoring essential design elements of the trial in a way that preserves credibility while providing the company with assurance that at the trial’s conclusion the basic objectives have a reasonably high likelihood of being achieved. In this capacity, the DMC can provide important feedback regarding design parameters, such as emerging trends showing lower than anticipated efficacy, unacceptable risk/benefit, or unanticipated trends in the control arm which could result in insufficient power to detect clinical efficacy.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Ron Kershner received his PhD in biostatistics from Cornell University and has worked in the areas of biostatistics and data management in the pharmaceutical industry for over 25 years. He has worked for large pharma, biotech and clinical research organisations. Currently, Ron is Vice President of Biostatistics and Data Management at AAIPharma Inc. Through his career, Ron has participated in 24 NDA submissions and has served in various capacities in over 20 DMCs. Most recently, Ron served as Chairman of a DMC, providing efficacy and safety oversight for two Phase III studies in kidney transplantation.
spacer
Ron Kershner
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Medovate announces distribution agreement with LTR Medical for sales of SAFIRA® in Australia and New Zealand

08 September 2020: Medovate, the medical device development company, has concluded a distribution agreement with Brisbane-based LTR Medical which will provide exclusivity for SAFIRA® (SAFer Injection for Regional Anaesthesia) in Australia and New Zealand.
More info >>

White Papers

Exploring Protein Stability by nanoDSF

NanoTemper Technologies GmbH

nanoDSF determines thermal and chemical protein stability with ultra-high resolution and with unmatched reproducibility. The detection of the intrinsic tryptophan and tyrosin fluorescence enables measurements at close-to-native conditions in any buffer, even in the presence of detergents. nanoDSF is applied in antibody engineering, membrane protein research, formulation and quality control.
More info >>

 
Industry Events

CPhI Festival of Pharma

5-16 October 2020, Virtual

A virtual gathering for the pharmaceutical industry, the CPhI Festival of Pharma has been created to fill the gap left by in-person events at a time when travel and gatherings are off the cards.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement